Fig. 5: Longitudinal profile of antibodies against the spike protein in hematological patients receiving prior or ongoing rituximab treatment. | Blood Cancer Journal

Fig. 5: Longitudinal profile of antibodies against the spike protein in hematological patients receiving prior or ongoing rituximab treatment.

From: Production and persistence of specific antibodies in COVID-19 patients with hematologic malignancies: role of rituximab

Fig. 5

Spike antibody (S-Ab) levels were determined at 1, 3, and 6 months after nasal swabs became PCR-negative in hematological patients receiving prior (a) or ongoing rituximab treatment (b). The cutoff value for determining seropositivity for S-Ab is shown by the dotted lines.

Back to article page